Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.65    0.00 (0.00%)
Bid:
1.55
Ask:
1.75
Spread: 0.20 (12.903%)
Market Cap: £264.66k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Settlement and CVA

30 Aug 2022 18:19

RNS Number : 6596X
Iconic Labs PLC
30 August 2022
 

For immediate release

ICONIC LABS PLC - IN ADMINISTRATION

Settlement of Disputes and Company Voluntary Arrangement

 

The Joint Administrators provide the following update on the administration, settlement of disputes and convening of a General Meeting:

Disputes with D sefton & Greencastle MediA

A Settlement Agreement has been entered into between the Company, Greencastle Media, Arch Capital Partners LLP, Mr D Sefton and the European High Growth Opportunities Securitization Fund. As a result, all litigation proceedings have been dismissed, and all claims, counter claims, including defamation claims, among the parties, have been waived or will be waived upon the CVA being approved.

 

A separate announcement has been issued relating to the retraction of claims made against David Sefton and the former directors of Iconic Labs PLC.

 

COMPANY VOLUNTRAY ARRANGEMENT PROPOSALS

Company Voluntary Arrangement ("CVA") Proposals have been finalised and are being sent out to all creditors and shareholders, together with Notices of Meetings of creditors and shareholders to consider the CVA which to be held on 22 September 2022, at 10.30 am and 2.00pm respectively. The General Meeting of Shareholders will include a Resolution to approve the CVA will be held at the offices of KWM Europe LLP, 9th Floor, 24 Monument Street, London, EC3R 8AJ. The meeting of shareholders will, if the CVA is passed, consider, in addition to a resolution to approve the CVA, resolutions to authorise the directors of the Company to allot shares and to disapply statutory pre-emption rights. These resolutions relating to the issuance of shares by the Company will be crucial to the Company's ability to raise future finance, including from the European High Growth Opportunities Securitization Fund as part of the "future funding" as described below.

A Form of Proxy must be completed, signed and received by Company's registrar, SLC Registrars, in accordance with the shareholders' circular.

 

FUTURE FUNDING

Subject to the CVA being approved and other resolutions being passed by shareholders at the General Meeting, the European High Growth Opportunities Securitization Fund have agreed to provide funding for the CVA and general working capital purposes, under existing and new facilities, subject to certain conditions precedent.

 

RE-LISTING OF SHARES

If the CVA is approved, the Board will enter into discussions with the Financial Conduct Authority with a view to the Company's suspension of shares being lifted. The Company's annual accounts for the year ended 30 June 2021 have been prepared and once audited will be published along with interim accounts to 31 December 2021.

 

ADMINISTRATION

If the CVA is approved, it is anticipated that the Administration will be brought to an end as soon as is practically possible.

 

 

30 August 2022

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSDAFMSEESELA
Date   Source Headline
11th Jan 201912:23 pmRNSHolding(s) in Company
10th Jan 201911:19 amRNSHolding(s) in Company
9th Jan 201912:06 pmRNSHolding(s) in Company
15th Nov 20181:03 pmRNSGM Results
14th Nov 20186:07 pmRNSHolding(s) in Company
6th Nov 20182:18 pmRNSIssue and Allotment of Ordinary Shares
31st Oct 20187:00 amRNS3rd Conversion of Bond
30th Oct 20186:10 pmRNSReplacement - Notice of General Meeting
30th Oct 20184:25 pmRNSNotice of AGM
30th Oct 20182:05 pmRNSSecond Price Monitoring Extn
30th Oct 20182:00 pmRNSPrice Monitoring Extension
30th Oct 20187:00 amRNSWideacademy Restructuring
29th Oct 20184:33 pmRNSHolding(s) in Company
23rd Oct 20188:27 amRNSConversion of Bond
22nd Oct 20183:27 pmRNSConversion of bonds
22nd Oct 20187:00 amRNSSmart Cells Deal
19th Oct 20189:20 amRNSHolding(s) in Company
18th Oct 201812:47 pmRNSBoard Restructuring
17th Oct 20184:48 pmRNSHolding(s) in Company
1st Oct 201811:00 amRNSPrice Monitoring Extension
28th Sep 20183:30 pmRNSHolding(s) in Company
27th Sep 20184:40 pmRNSSecond Price Monitoring Extn
27th Sep 20184:35 pmRNSPrice Monitoring Extension
27th Sep 201810:40 amRNSNotification of transactions of Directors
27th Sep 20187:10 amRNSInterim Results
27th Sep 20187:00 amRNSFinancing Agreement
30th Jul 20187:00 amRNSCellPlan Launch in Spain
9th Jul 20187:01 amRNSBoard Changes
9th Jul 20187:00 amRNSHolding(s) in Company
29th Jun 20183:00 pmRNSResult of AGM
28th Jun 201810:30 amRNSResult of General Meeting
15th Jun 20187:00 amRNSAlign Research Initiation of Coverage
12th Jun 20186:25 pmRNSProspectus and Notice of General Meeting
11th Jun 20189:00 amRNSLive Market Bookbuild Closes
11th Jun 20187:30 amRNSRestoration Widecells Group Plc
11th Jun 20187:00 amRNSUpdate Regarding Placing and Financial Position
6th Jun 20183:00 pmRNSNotice of AGM
5th Jun 20187:00 amRNSAudited Preliminary Results
21st May 20187:00 amRNSFinal Results Update
10th May 201810:30 amRNSPlacing to Raise £1.47m and Live Market Bookbuild
3rd May 20187:30 amRNSSuspension Widecells Group
1st May 20187:02 amRNSAnnual Accounts and Fundraising Update
26th Mar 20187:00 amRNSLandmark deal to launch CellPlan insurance in Asia
19th Mar 20187:00 amRNSGranted Innovate UK KTP for Stem Cell Research
27th Feb 20187:00 amRNSLicence Award from the Human Tissue Authority
19th Feb 20187:00 amRNSBoard Changes and Launch of Wideacademy Platform
21st Dec 20177:00 amRNSCorporate Update
2nd Nov 20177:00 amRNSRevenue generation with White Apex agreement
12th Oct 20177:00 amRNSCellPlan expansion, e-commerce platform launch UK
11th Oct 20177:00 amRNSPartner Secured to Expand into MENA & Asia-Pacific

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.